Brian Schwartz

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 4

Top Topics

Tyrosine Kinase

Chronic Lymphocytic Leukemia

Top Venues

Cancer discovery

Cold Spring Harbor molecular case studies

This page only lists publications with an associated author ORCID identifier.

Publications

Jennifer A Woyach, Deborah M Stephens, Ian W Flinn, Seema A Bhat, Ronald E Savage, Feng Chai, Sudharshan Eathiraj, Sean D Reiff, Elizabeth M Muhowski, Lindsey Granlund, Lyndsey Szuszkiewicz, Wayne Wang, Brian Schwartz, Razi Ghori, Mohammed Z H Farooqui, John C Byrd
First in Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma. Cancer discovery (2023)
Leslie G Biesecker, Matthew Edwards, Sheridan O'Donnell, Paula Doherty, Thomas MacDougall, Kate Tith, Julia Kazakin, Brian Schwartz
Clinical report: one year of treatment of Proteus syndrome with miransertib (ARQ 092). Cold Spring Harbor molecular case studies 6 (1) (2020)
Devki Nandan, Naixin Zhang, Yi Yu, Brian Schwartz, Stella Chen, Peter E Kima, Neil E Reiner
Miransertib (ARQ 092), an orally-available, selective Akt inhibitor is effective against Leishmania. PloS one 13 (11) (2018)
Sean D Reiff, Rose Mantel, Lisa L Smith, J T Greene, Elizabeth M Muhowski, Catherine A Fabian, Virginia M Goettl, Minh Tran, Bonnie K Harrington, Kerry A Rogers, Farrukh T Awan, Kami Maddocks, Leslie Andritsos, Amy M Lehman, Deepa Sampath, Rosa Lapalombella, Sudharshan Eathiraj, Giovanni Abbadessa, Brian Schwartz, Amy J Johnson, John C Byrd, Jennifer A Woyach
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation. Cancer discovery 8 (10) (2018)